CD19 and esophageal cancer: The clinical success of CD19-CAR-engineered T cells directed against CD19+ B cell malignant cells has been well documented [124,125] and will likely lead to clinical approval next year by the Food and Drug Administration in the U.S. Similarly, for other tumor entities, such as melanoma, breast, colorectal, and esophageal cancers, the first evidence of positive clinical outcomes following adoptive TCR transgenic T cell therapy has been reported [126].